|
Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601). |
|
|
|
Research Funding - AstraZeneca (Inst) |
Travel, Accommodations, Expenses - Amgen; AstraZeneca |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Lilly; MSD; Takeda |
Consulting or Advisory Role - Abbvie; AstraZeneca; Lilly; MSD; Takeda |
Speakers' Bureau - AstraZeneca |
Research Funding - BeiGene (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; Novartis; Pfizer |
Travel, Accommodations, Expenses - Novartis |
|
|
Speakers' Bureau - AstraZeneca; Roche |
|
|
|
Consulting or Advisory Role - MSD; Takeda |
Research Funding - AstraZeneca |
Travel, Accommodations, Expenses - Amgen |
|
|
|
Consulting or Advisory Role - AstraZeneca |
Travel, Accommodations, Expenses - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca/MedImmune |
Consulting or Advisory Role - AstraZeneca/MedImmune |
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck Serono (Inst); Regeneron (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
Honoraria - Merck Sharp & Dome |
Patents, Royalties, Other Intellectual Property - Uniquest |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Tilray (Inst) |
Travel, Accommodations, Expenses - Medivation/Pfizer |
|
|
Travel, Accommodations, Expenses - BeiGene; Roche; Roche |